{"id":3508,"date":"2018-10-30T17:36:17","date_gmt":"2018-10-30T12:06:17","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3508"},"modified":"2021-07-24T12:57:06","modified_gmt":"2021-07-24T07:27:06","slug":"notizia-78","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-78","title":{"rendered":"Notizia"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>TherapeuticsMD bags FDA approval for hormone therapy<\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>FDA<\/strong> has nodded hormone therapy of <strong>TherapeuticsMD<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/hot-flashes-market\"><strong>hot flashes<\/strong> <\/a>that are associated with menopause. <strong>Bijuva<\/strong> is an oral treatment that contains molecularly identical (bio-identical) versions of the hormones\u00a0estradiol and progesterone for menopausal women with a uterus\u00a0experiencing moderate-to-severe vasomotor symptoms. It was approved with a warning written on it for cardiovascular disorders, probable dementia as well as breast and endometrial cancer. The drug will be made available next year.<\/p>\n<p style=\"text-align: justify;\"><strong>Pfizer and Novartis collaborate to aim NASH <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Pfizer\u00a0<\/strong>declared plans to challenge the un\u00adtreated fatty liver dis\u00adease with\u00a0<strong>No\u00advar\u00adtis<\/strong>. A build-up of excess fat in the liver is the characterization of <strong>NASH<\/strong> that in\u00adduces\u00a0chronic in\u00adflam\u00adma\u00adtion and even\u00adtu\u00adally leads to\u00a0scar\u00adring, which lead to cir\u00adrho\u00adsis, liver fail\u00adure, can\u00adcer and death. The dis\u00adease is as\u00adso\u00adci\u00adated with obe\u00adsity and di\u00ada\u00adbetes that will obscure\u00a0<strong>he\u00adpati\u00adtis C<\/strong> as the lead\u00ading rea\u00adson for liver trans\u00adplants by 2020. It is difficult to di\u00adag\u00adnose in the early stages, because of which es\u00adti\u00admating its preva\u00adlence is hard, however, stud\u00adies indicate that it af\u00adflicts up to 12% of\u00a0the adult pop\u00adu\u00adla\u00adtion in de\u00advel\u00adoped coun\u00adtries. There are no ap\u00adproved drugs for the dis\u00adease yet.<\/p>\n<p style=\"text-align: justify;\"><strong>The cholesterol drug of Esperion passes the last safety impediment<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Esperion<\/strong>, American- based pharmaceutical company, is all set to make the last step in marketing application at the FDA. However, the recent batch of positive safety and efficacy data will not banish the questions on its sales strategy. The drug arm had a moderate drop in LDL of 18% with a 19% cut in <strong>high-sensitivity C-reactive protein<\/strong>. In Esperion studies, the therapy fits precisely between the generics that rule the market and the PCSK9s that have had difficulty finding traction, spurring some deep discounting that could spell trouble for Esperion.<\/p>\n<p style=\"text-align: justify;\"><strong>Roche extends its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab<\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>Genentech <\/strong>of<strong> Roche<\/strong> has secured success to challenge <strong>Regeneron<\/strong> and the Big Pharma contender, Novartis. The Researchers told that their bispecific <strong>Ang-2\/VEGF drug <\/strong>faricimab came up with an improved profile over the player, Lucentis as a long-acting drug for wet AMD. And they scored on long-acting 16-week data, while Regeneron and Novartis have been duking it out over the 12-week niche. <strong>Eylea<\/strong> has been the leader of this market, giving Regeneron the profitable franchise market it needs to establish the company\u2019s pipeline and new product offerings. Novartis has been making a mark with <strong>brolucizumab<\/strong> (RTH258).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>TherapeuticsMD bags FDA approval for hormone therapy The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an oral treatment that contains molecularly identical (bio-identical) versions of the hormones\u00a0estradiol and progesterone for menopausal women with a uterus\u00a0experiencing moderate-to-severe vasomotor symptoms. It was approved with a warning written [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3440,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2060,2055,2061,2058,1102,704,1135,1394,2059,2054,1469,423,460,504,524,2053],"industry":[17225],"therapeutic_areas":[17240,17244,17236,17411],"class_list":["post-3508","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ang-2-vegf-drug-faricimab","tag-bijuva","tag-brolucizumab","tag-esperion","tag-eylea","tag-fda","tag-genentech","tag-hepatitis-c","tag-high-sensitivity-c-reactive-protein","tag-hot-flashes","tag-nash","tag-novartis","tag-pfizer","tag-regeneron","tag-roche","tag-therapeuticsmd","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-ophthalmology","therapeutic_areas-otolaryngology","therapeutic_areas-womens-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 30\/10\/2018 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an oral treatment that contains.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-78\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 30\/10\/2018 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an oral treatment that contains.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-78\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-30T12:06:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"583\" \/>\n\t<meta property=\"og:image:height\" content=\"310\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 30\/10\/2018 - DelveInsight Business Research","description":"The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an oral treatment that contains.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-78","og_locale":"en_US","og_type":"article","og_title":"Notizia 30\/10\/2018 - DelveInsight Business Research","og_description":"The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an oral treatment that contains.....","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-78","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-10-30T12:06:17+00:00","article_modified_time":"2021-07-24T07:27:06+00:00","og_image":[{"width":583,"height":310,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-78","url":"https:\/\/www.delveinsight.com\/blog\/notizia-78","name":"Notizia 30\/10\/2018 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-78#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-78#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2.png","datePublished":"2018-10-30T12:06:17+00:00","dateModified":"2021-07-24T07:27:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an oral treatment that contains.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-78"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-78#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2.png","width":583,"height":310,"caption":"Hot flashes"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ang-2\/VEGF drug faricimab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bijuva<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">brolucizumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Esperion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eylea<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genentech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hepatitis c<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">high-sensitivity C-reactive protein<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hot flashes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TherapeuticsMD<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Ang-2\/VEGF drug faricimab<\/span>","<span class=\"advgb-post-tax-term\">Bijuva<\/span>","<span class=\"advgb-post-tax-term\">brolucizumab<\/span>","<span class=\"advgb-post-tax-term\">Esperion<\/span>","<span class=\"advgb-post-tax-term\">Eylea<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Genentech<\/span>","<span class=\"advgb-post-tax-term\">hepatitis c<\/span>","<span class=\"advgb-post-tax-term\">high-sensitivity C-reactive protein<\/span>","<span class=\"advgb-post-tax-term\">hot flashes<\/span>","<span class=\"advgb-post-tax-term\">NASH<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Regeneron<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">TherapeuticsMD<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 30, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 30, 2018 5:36 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3508"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3508\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3440"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3508"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3508"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}